

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 April 28; 23(16): 2819-3010



**EDITORIAL**

- 2819 High throughput RNA sequencing utility for diagnosis and prognosis in colon diseases  
*Gao M, Zhong A, Patel N, Alur C, Vyas D*
- 2826 Transition of early-phase treatment for acute pancreatitis: An analysis of nationwide epidemiological survey  
*Hamada S, Masamune A, Shimosegawa T*

**DIAGNOSTICS ADVANCES**

- 2832 Non-invasive evaluation of intestinal disorders: The role of elastographic techniques  
*Branchi F, Caprioli F, Orlando S, Conte D, Fraquelli M*

**REVIEW**

- 2841 Oxidative stress, antioxidants and intestinal calcium absorption  
*Diaz de Barboza G, Guizzardi S, Moine L, Tolosa de Talamoni N*
- 2854 Importance of antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection  
*Arslan N, Yilmaz Ö, Demiray-Gürbüz E*
- 2870 Strategies used by *helicobacter pylori* to establish persistent infection  
*Talebi Bezin Abadi A*

**MINIREVIEWS**

- 2883 Magnetic anchor guidance for endoscopic submucosal dissection and other endoscopic procedures  
*Mortagy M, Mehta N, Parsi MA, Abe S, Stevens T, Vargo JJ, Saito Y, Bhatt A*

**ORIGINAL ARTICLE****Basic Study**

- 2891 Droplet digital PCR for quantification of *ITGA6* in a stool mRNA assay for the detection of colorectal cancers  
*Herring E, Kanaoka S, Tremblay E, Beaulieu JF*
- 2899 Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound  
*Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D*

- 2912 *In vitro* and *in vivo* antioxidative and hepatoprotective activity of aqueous extract of Cortex Dictamni  
*Li L, Zhou YF, Li YL, Wang LL, Arai H, Xu Y*

- 2928 Comparison of the analgesic effects between electro-acupuncture and moxibustion with visceral hypersensitivity rats in irritable bowel syndrome  
*Zhao JM, Li L, Chen L, Shi Y, Li YW, Shang HX, Wu LY, Weng ZJ, Bao CH, Wu HG*

- 2940 Study of the effects of nesfatin-1 on gastric function in obese rats  
*Yang GT, Zhao HY, Kong Y, Sun NN, Dong AQ*

### Case Control Study

- 2948 Recent upper gastrointestinal panendoscopy increases the risk of pyogenic liver abscess  
*Tsai MJ, Lu CL, Huang YC, Liu CH, Huang WT, Cheng KY, Chen SCC*

### Retrospective Cohort Study

- 2957 Gutuo Jiejiu decoction improves survival of patients with severe alcoholic hepatitis: A retrospective cohort study  
*Mou HY, Nie HM, Hu XY*

### Retrospective Study

- 2964 One year experience with computer-assisted propofol sedation for colonoscopy  
*Lin OS, La Selva D, Kozarek RA, Tombs D, Weigel W, Beecher R, Koch J, McCormick S, Chiorean M, Drennan F, Gluck M, Venu N, Larsen M, Ross A*

- 2972 Ninety-day readmissions after inpatient cholecystectomy: A 5-year analysis  
*Manuel-Vázquez A, Latorre-Fragua R, Ramiro-Pérez C, López-Marciano A, Al-Shwely F, De la Plaza-Llamas R, Ramia JM*

### Clinical Trials Study

- 2978 Early hepatitis B viral DNA clearance predicts treatment response at week 96  
*Fu XY, Tan DM, Liu CM, Gu B, Hu LH, Peng ZT, Chen B, Xie YL, Gong HY, Hu XX, Yao LH, Xu XP, Fu ZY, He LQ, Li SH, Long YZ, Li DH, Gu JL, Peng SF*

- 2987 Effects of Chinese herbal medicine Xiangbin prescription on gastrointestinal motility  
*Jiang Z, Cao LX, Liu B, Chen QC, Shang WF, Zhou L, Li DY, Guo DA, Chen ZQ*

### Observational Study

- 2995 Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice  
*Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN*

**CASE REPORT****3003** Protein-losing pseudomembranous colitis with cap polyposis-like features*Kreisel W, Ruf G, Salm R, Lazaro A, Bengsch B, Globig AM, Fisch P, Lassmann S, Schmitt-Graeff A*

## Contents

*World Journal of Gastroenterology*  
Volume 23 Number 16 April 28, 2017

### ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Dar-In Tai, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taipei 105, Taiwan

### AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

### INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports<sup>®</sup> released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

### FLYLEAF

#### I-IX Editorial Board

### EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Cui-Hong Wang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Yuan Qi*  
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

#### EDITORS-IN-CHIEF

**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

#### EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

#### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Yuan Qi, Vice Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

#### PUBLISHER

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE  
April 28, 2017

#### COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

#### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

#### INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION  
<http://www.f6publishing.com>

## Strategies used by *helicobacter pylori* to establish persistent infection

Amin Talebi Bezmin Abadi

Amin Talebi Bezmin Abadi, Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-111, Iran

**Author contributions:** Talebi Bezmin Abadi A designed the research, analyzed the data and wrote the article.

**Conflict-of-interest statement:** Author declares no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Amin Talebi Bezmin Abadi, PhD, Assistant Professor, Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-111, Iran. [amin.talebi@modares.ac.ir](mailto:amin.talebi@modares.ac.ir)  
Telephone: +98-21-82884883  
Fax: +98-21-82884883

Received: December 5, 2016

Peer-review started: December 6, 2016

First decision: January 10, 2017

Revised: February 1, 2017

Accepted: February 16, 2017

Article in press: February 16, 2017

Published online: April 28, 2017

### Abstract

*Helicobacter pylori* (*H. pylori*) is a Gram-negative and motile bacterium that colonizes the hostile microniche of the human stomach, then persists for the host's entire life, if not effectively treated. Clinically, *H. pylori* plays a

causative role in the development of a wide spectrum of diseases including chronic active gastritis, peptic ulceration, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue lymphoma. Due to the global distribution of *H. pylori*, it is no exaggeration to conclude that smart strategies are contributing to adaptation of the bacterium to its permanent host. Thirty-four years after the discovery of this bacterium, there are still many unanswered questions. For example, which strategies help the bacterium to survive in this inhospitable microniche? This question is slightly easier to answer if we presume the same clinical concept for both persistent infection and disease. Understanding the mechanisms governing *H. pylori* persistence will improve identification of the increased risk of diseases such as gastric cancer in patients infected with this bacterium. A well-defined and long-term equilibrium between the human host and *H. pylori* allows bacterial persistence in the gastric microniche; although this coexistence leads to a high risk of severe diseases such as gastric cancer. To escape the bactericidal activity of stomach acid, *H. pylori* secretes large amounts of surface-associated and cytosolic urease. The potential to avoid acidic conditions and immune evasion are discussed in order to explain the persistence of *H. pylori* colonization in the gastric mucosa, and data on bacterial genetic diversity are included. Information on the mechanisms related to *H. pylori* persistence can also provide the direction for future research concerning effective therapy and management of gastroduodenal disorders. The topics presented in the current review are important for elucidating the strategies used by *H. pylori* to help the bacterium persist in relation to the immune system and the many unfavorable features of living in the gastric microniche.

**Key words:** *Helicobacter pylori*; Gastric microniche; Persistent infection; Gastric cancer

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.



**Core tip:** *Helicobacter pylori* (*H. pylori*) infections are thought to cause severe gastroduodenal disorders which are the main outcome of this interaction between the host and this microorganism. The bacterium has developed interesting strategies which allow it to efficiently colonize the gastric mucosa leading to persistent infection. In this review, we aim to look at the five major reported strategies leading to the persistent survival of *H. pylori* within gastric epithelial cells.

Talebi Bezmin Abadi A. Strategies used by *Helicobacter pylori* to establish persistent infection. *World J Gastroenterol* 2017; 23(16): 2870-2882 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i16/2870.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i16.2870>

## INTRODUCTION

The groundbreaking discovery of a Gram-negative bacterium by Marshall and Warren changed the gastroenterologists' view regarding the historic dogma that the stomach was a sterile organ<sup>[1]</sup>. Phylogenetic analysis emphasized the global distribution of the bacterium from East Africa to other continents thousands of years ago<sup>[2-5]</sup>. *Helicobacter pylori* (*H. pylori*) which was previously called *Campylobacter pyloridis* is mostly acquired during childhood and it has been genetically proved that it can be transmitted within families<sup>[4]</sup>. *H. pylori* is a  $\epsilon$ -proteobacterium that colonizes the human stomach with patchy distribution and is mainly found in the antrum rather than the fundus<sup>[6]</sup>. Many published international guidelines recommend treatment of the bacterium with effective antibiotics<sup>[7-11]</sup>. Both *in vitro* and *in vivo* evidence in addition to epidemiologic data have confirmed that *H. pylori* is the main cause of both gastric and duodenal ulcers, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma<sup>[12-15]</sup>. Due to the high prevalence of *H. pylori* worldwide and success of this long-term commensalism, it is no exaggeration to assume that complex strategies are involved in efficient colonization in the host. Virulence factors involved in the establishment of a persistent infection are shown in Table 1. As shown, an adhesion or secreted protein can be a determining factor in successful persistent colonization. This concept raises a challenging question concerning how *H. pylori* can persistently colonize the stomach in such unfavorable conditions. In the current review, we discuss the five observed strategies leading to persistent survival within gastric epithelial cells.

## FIRST STRATEGY: ESCAPING GASTRIC ACIDITY

The human gastric lumen is known to consist of a

**Table 1 Major virulence factors involved in the persistence of *Helicobacter pylori***

Virulence factors	Roles in persistent infection
OipA	Induces pro-inflammatory cytokines In combination with CagA, causes disruption of cell tight junctions
VacA	Increases IL8 expression and causes inflammation Contributes to long-term colonization Cell proliferation and elongation Increases the level of MAPK signaling
CagA	Stimulates the NF- $\kappa$ B pathway Induces apoptosis Induces pro-inflammatory cytokines Disrupts cell tight junctions Increases mucosal inflammation
BabA	Leads to effective cell adherence Mediates in the effective interaction between <i>H. pylori</i> and epithelial cells
DupA	Induces pro-inflammatory cytokines Induces apoptosis
GGT	Contributes to long-term gastric colonization Induces immune response tolerance
SabA	Mediates the effective interaction between <i>H. pylori</i> and epithelial cells

MAPK: Mitogen-activated protein kinase; NF- $\kappa$ B: Nuclear factor- $\kappa$ B; *H. pylori*: *Helicobacter pylori*.

large variety of physical and biochemical barriers to provide an unfavorable environment for all types of ingested microbes<sup>[16]</sup>. Successful gastric colonization by any microorganism in this microniche is due to the existence of various abilities to avoid hostile acidic conditions and the viscous mucosal layer<sup>[17,18]</sup>. To do this, *H. pylori* harbors specific features leading to successful colonization. In the following paragraphs, we discuss how this bacterium can cause persistent infection with a focus on acidity avoidance.

## UREASE AS THE FIRST WEAPON AGAINST ACIDITY

The acidity of the stomach (pH 1-2) is the first danger to threaten bacterial survival in the stomach<sup>[14,17,19]</sup>. *H. pylori* is able to survive at approximately pH 5 which can kill many digested organisms within a few minutes after acid exposure. This is the main adaptive feature of this bacterium which facilitates its survival in the gastric microniche. *H. pylori* growth is limited in neutral pH, but can survive in acidic pH due to an increase in periplasmic pH and secretion of a large amount of urease enzyme<sup>[18,20]</sup>. Urease is a key feature in the capacity of *H. pylori* to avoid gastric acidity. To avoid the bactericidal activity of acid, *H. pylori* secretes large amounts of surface-associated and cytosolic urease<sup>[6]</sup>. However, hydrolysis of urea (occurring in the gastric lumen) produces large amounts of ammonia, which is then protonated to create ammonium, thus creating a neutral bacterial microniche<sup>[21]</sup>. In the presence of urea, pH is shifted to 2-6 and *H. pylori* can

survive in the gastric microniche. In contrast, in the absence of urea, *H. pylori* can grow in the pH range of 6-8 and can even survive in the pH range of 4-8.5. Urea is imported through a specific channel, and with urease, ammonia will fill the entire cytosol and even bacterial periplasm<sup>[22,23]</sup>. *H. pylori* urease gene cluster consists of two major genes, ureA and ureB, and five accessory genes, ureI, ureE, ureF, ureG, and ureH. These accessory subunits are associated with urea absorption<sup>[16,18,21,24]</sup>. Urease is a nickel-binding hexamer of UreA and UreB. It has been reported that *H. pylori* can change the expression of certain genes (associated with the synthesis of ammonium ion) including arginase, urease and formamidase after exposure to hostile gastric acidic conditions<sup>[18]</sup>. The production of urease in 10% of bacterial proteomes enables it to hydrolyze large amounts of gastric urea to generate ammonia and CO<sub>2</sub>, causing a sharp increase in the pH around *H. pylori*<sup>[25]</sup>. However, in response to low pH by the ArsSR two-component system, production of ammonia can be continued by formamidase in addition to urease by the hydrolysis of short-chain amino acids, while arginase hydrolyzes L-arginine to L-ornithine and urea<sup>[26,27]</sup>. To establish persistent infection, after entering the gastric lumen, the bacterium should be able to penetrate and infiltrate the viscous mucosal layer<sup>[28,29]</sup>. Interestingly, mucosal viscosity is highly dependent on acidity. In general, in more acidic pH, mucus is stronger than at pH 4. Enzymatic activity governed by *H. pylori* facilitates bacterial penetration into the aggregated mucus. Subsequent diffusion of ammonia in the stomach provides an opportunity for *H. pylori* to penetrate deeply using corkscrew propulsion due to its flagella. The helical shape of the bacterium is another factor affecting its successful evasion of acid<sup>[30]</sup>. Due to low permeability of the mucosal layer, there is a scarcity of essential nutrients (for example Fe<sup>3+</sup>) in the stomach for all ingested microorganisms<sup>[13,16,18,21,22]</sup>. The release of large amounts of urease is a smart strategy adopted by *H. pylori* to weaken the integrity of the mucus to facilitate deep penetration to reach the nutrient enriched region. Moreover, moving into deeper layers gives the bacterium the opportunity to avoid the acidic conditions on the surface of the lumen; another strategy which increases the viability of this bacterium<sup>[6,13,31]</sup>. Thus, *H. pylori* would not survive in the stomach without its potential to escape high acidity which is not observed in any other microorganisms.

#### Intracellular or extracellular life

During the time research had been undertaken on *H. pylori* colonization in the human stomach, no clear evidence has been published to indicate that *H. pylori* is an invasive organism in the human gastric microniche<sup>[4,6,19,32]</sup>. Following the assessment of a large number of *in vivo* and *in vitro* studies, we suggest that *H. pylori* is a noninvasive gastric pathogen<sup>[33,34]</sup>. Interestingly, *H. pylori* is able to repopulate the

extracellular environment following bacterial clearance (for example with effective antibiotics) of the gastric lumen, suggesting it may be better described as a facultative intracellular microbe<sup>[35]</sup>. To date, no direct evidence on *H. pylori* replication in gastric cells has been reported<sup>[36]</sup>. However, despite the progress already achieved, more *in vitro* experiments are required before we can conclude that the intracellular effect of *H. pylori* is a strategy involved in long-term persistence in gastric epithelial cells. However, it can be assumed that *H. pylori* is a facultative intracellular bacterium rather than an extracellular organism. As a temporary strategy to avoid chemical and physical barriers, *H. pylori* can transiently enter the intracellular space for a short time to reduce exposure duration to antibiotics, acidic conditions and the immune response<sup>[37]</sup>. Moreover, as *H. pylori* is optimally evolved to reduce its exposure to acidic gastric conditions, it can localize in mucus close to the epithelial surface where acidity is tolerable for longer survival. This strategy adopted by the microbe further highlights the importance of research in finding effective antibiotics to treat this organism.

#### Direct contact with host cells

By involving various surface proteins, *H. pylori* can bind to epithelial cells<sup>[38]</sup>. BabA is a major outer membrane protein and is one of these contributing proteins (Figures 1-3)<sup>[39,40]</sup>. Interestingly, there are other adhesion molecules which facilitate attachment of the bacterium to epithelial cells<sup>[41]</sup>. Bacterial secreted lectin is another binding factor which binds to the sialic residues of laminin<sup>[42]</sup>. A cascade pathway allows the successful irreversible attachment of *H. pylori* to polarized epithelial cells (Figure 2)<sup>[43]</sup>. Small cytoplasmic changes can be observed following direct contact between *H. pylori* and host cells. Following first contact of the bacterium with the plasma membrane and rearrangement of the cellular cytoskeleton, an extension of the plasma membrane can engulf a part of the bacterium<sup>[38]</sup>. Undoubtedly, certain bacterial factors such as *cagA* and *dupA* are involved in the above processes; however, data regarding details of this contribution are lacking<sup>[44]</sup>. Interestingly, it was noted that only a small fraction of available *H. pylori* strains in the gastric mucosa can attach to the surface. Although *H. pylori* adherence is mediated by candidate surface proteins (e.g., AlpA, AlpB, DupA, BabA, OipA, SabA and HopZ), no specific molecule has been shown to be essential in adhesive mechanisms<sup>[45,46]</sup>. For example, *H. pylori* SabA supports the release of nutrients in the apical side of epithelial cells for bacterial survival in the stomach. This nutrient release is in parallel with translocated CagA protein which can induce inflammation in infected cells<sup>[47]</sup>. Different expression of adhesion molecules occurs among *H. pylori* strains suggesting various adaptations induced by genetic recombination, on/off switching of gene






Figure 1 Basic overview of the events leading to the successful colonization of *Helicobacter pylori*.




Figure 2 Subsequent activated events causing inflammation in chronic infection by *Helicobacter pylori*.

expression. It is clear that bacterial attachment is an inevitable step in the establishment of *H. pylori* infection, although determining the molecules involved is not easy. New technologies in the near future will reveal further details of the complex initial process in persistent *H. pylori* infection.

## SECOND STRATEGY: HELICAL SHAPE

The helical shape of *H. pylori* has been suggested to provide a mechanical advantage for penetrating the viscous stomach mucus layer. Special cross-linkages in bacterial peptidoglycan can result in an efficient screw-like movement to facilitate *H. pylori* survival in the viscous environment of the stomach<sup>[48]</sup>. Consistent with this, *H. pylori* typically possesses a helical morphology and multiple uni-polar flagella. In an animal model, *H. pylori* cell shape mutants showed impaired stomach colonization indicating the importance of bacterial shape in motility and adherence<sup>[49]</sup>. The combination of a curved structure and cell elongation provides *H. pylori* with a suitable helical body shape. To date, our

knowledge indicates that a certain number of genes such as Ccrp89, Ccrp58, Ccrp1142 and Ccrp1143 are involved in *H. pylori* morphology<sup>[48]</sup>. Thus, any mutations in these genes can cause a deficiency in bacterial motility and shape<sup>[50]</sup>. It should be noted that the helical shape in addition to flagella are a major part of the successful penetration process.

## THIRD STRATEGY: THE PRESENCE OF FLAGELLA (MOTILITY)

To avoid elimination by regular gastric turnover, persistent infection is dependent on bacterial movement. *H. pylori* is mostly distributed within approximately 30 µm of mucosal epithelial cells and its histopathologic effects can be observed within the gastric crypts. During the last decade, *H. pylori* flagella have been widely investigated, and current knowledge demonstrates the critical role of these organelles in the colonization and establishment of persistent infection<sup>[43]</sup>. Extensive isogenic mutant studies have shown the role of intact flagellar apparatus in




Figure 3 Flowchart of the strategies involved in persistent infection.

governing *H. pylori* infection, especially long-term infection<sup>[51]</sup>. *H. pylori* is an actively motile organism which has the ability to move between different regions of the stomach. Furthermore, flagella give the bacterium the potential for penetration which is necessary to avoid acidic pressure on the surface of the gastric mucosa<sup>[52]</sup>. Due to the combination of more than 39 genes in the *H. pylori* genome, 3-5 tuft-like flagella appear on the side of the bacterium. These flagella consist of a basal body, hook, and flagellar filament<sup>[53]</sup>. The deletion or any other changes in the genes related to the flagella can produce non-motile *H. pylori* which is unable to effectively colonize gastric mucosa<sup>[54]</sup>. In order to move both in counterclockwise (CCW) and clockwise (CW) directions, *H. pylori* requires a rotating movement around the filament<sup>[55]</sup>. The existence of polar flagella in *H. pylori* is a requirement for persistent infection. Following entry into the stomach, the bacterium has a durable acid-tolerance range<sup>[56]</sup>. *H. pylori* is tolerant to weakly acidic conditions in the stomach which occur after ingestion. Given that ammonia is produced by bacterial urease, the rheologic properties of the gastric mucin changes allowing penetration of *H. pylori* into the gastric mucosa using flagellated motility and its helical shape. The detailed mechanism by which *H. pylori* weakens mucus viscosity is not fully understood, but we now know that loss of tightness on the side of polarized epithelial cells may be involved leading to several gastroduodenal diseases. Thus, movement of *H. pylori* is necessary in order to attach to epithelial cells<sup>[57]</sup>. Taken together, these findings show that the presence of flagella is useful for *H. pylori* to produce infection in the gastric mucosa, and urease is an essential enzyme guaranteeing successful bacterial penetration.

#### FOURTH STRATEGY: *H. PYLORI* EVASION OF THE HUMAN IMMUNE SYSTEM

During the relatively long time that *H. pylori* has been recognized, it is clear that long-term bacterial persistence is necessary to maintain successful existence of *H. pylori* against both innate and adaptive immune responses (Figure 4)<sup>[57,58]</sup>. Following successful colonization of gastric mucosal cells by *H. pylori*, host immune responses (both innate and acquired branches) are stimulated generating specific antibodies and activated Th cells. Thus, *H. pylori* is required to avoid both branches of the immune system to colonize the stomach for several years<sup>[59]</sup>. In addition to long-term infection, other diseases are caused by this microorganism. Any digestive diseases related to prolonged colonization by *H. pylori* can be due to adaptation between the microbe and human host<sup>[60]</sup>. We now know that subsequent to colonization by *H. pylori*, a percentage of the infected population can develop autoimmunity or immune system abnormalities<sup>[61-64]</sup>. These findings show bilateral effects between *H. pylori* and the human immune system. During the thousands of years of commensalism between humans and *H. pylori*, the bacterium has learned to subvert the immune response and it may serve as an example of bacterial evolution in maintaining its micro-territory in humans<sup>[62]</sup>. Taken together, these findings suggest that we should use the word "equilibrium" to define this status. In this equilibrium, *H. pylori* induces immune cells which cause minimum cell damage to shed nutrients onto the surface of the gastric mucosa for survival<sup>[32]</sup>. Cell damage following local superficial




Figure 4 Different impacts of *Helicobacter pylori* on the two branches of the human immune system.

gastritis occurs, but seems necessary for governing long-term colonization as the infection can cause minimum nutrient shedding which is required for bacterial survival in the harsh stomach environment. It should be noted that the microbe will be immediately eliminated by active immune cells<sup>[65]</sup>. In conclusion, bacterial persistence only occurs if *H. pylori* and the immune system co-adapt following successful immune evasion. In the next section, we briefly describe how *H. pylori* effectively avoids innate and adaptive immune responses.

## MECHANISMS OF IMMUNE EVASION BY *H. PYLORI* - INNATE IMMUNITY

Both components of the innate system (chemical and physical barriers) are involved in immune system responses against *H. pylori* in the stomach<sup>[66]</sup>. The gastric epithelial surface plays an active role in mucosal defense<sup>[67]</sup>. Immediately after entering the gastric epithelial cells, two major actions by the innate immune system work against *H. pylori*: (1) engulfment by phagocytes; and (2) chemical products of these cells include reactive nitrogen and oxygen<sup>[68,69]</sup>. Below, we focus on three different strategies adopted by *H. pylori* which facilitate establishment of persistent chronic infection in the gastric epithelium.

## EVASION OF PHAGOCYTE KILLERS

Although *H. pylori* is usually phagocytosed by macrophages, in comparison to other Gram negative microbes, *H. pylori* is highly resistant to killing by these cells during phagocytosis<sup>[70-73]</sup>. A virulent *H. pylori* strain (type I: *cagA*<sup>+</sup> *vacA*<sup>+</sup>) is more resistant to phagocytosis than other strains<sup>[74-76]</sup>. Accumulation of the bacterium in vesicles which produce megasomes is the main evidence for delayed phagocytosis<sup>[77,78]</sup>. Macrophage apoptosis can result in *H. pylori* escaping phagosomes<sup>[79]</sup>. As mentioned previously, *H. pylori* induces inflammation to provide nutrients, thus inflammation may be present for months or years.

Therefore, *H. pylori* needs to be well prepared to confront large numbers of phagocytes in the stomach due to the high rate of cell damage.

There are three proposed strategies which can help the bacterium to survive in this phagocyte-rich environment: (1) *H. pylori* induces mitochondrial-associated cell death in macrophages (mitochondrial dependent apoptosis)<sup>[80,81]</sup>; and (2) production of peroxiredoxin by AhpC gene actively defends the bacterium against NO products available in the gastric microniche<sup>[82-85]</sup>.

Similarly, *H. pylori* arginase due to substrate competition can reduce NO or O<sub>2</sub><sup>-</sup> radicals<sup>[86]</sup>. *In vitro* studies have shown that *H. pylori* activates macrophage nitric oxide synthase and thus apoptosis<sup>[87-89]</sup>. It has been shown that arginase-deficient bacteria are more sensitive to oxidative stress caused by macrophages<sup>[90,91]</sup>. Finally, *H. pylori* has adopted a smart strategy to inhibit polymorphonuclear neutrophil (PMN) and monocyte activation by involving CagA proteins (type IV secretion system)<sup>[92]</sup>. Furthermore, *cagA* positive strains produce more IL8, a trigger cytokine for inducing infiltration of inflammatory cells. Isogenic mutant experiments suggest the participation of VacA toxins in escape of the microbe from phagosomes<sup>[93]</sup>. Subsequent deactivation of PMNs and monocytes can cause interference in the innate immune response which is favorable for *H. pylori*<sup>[94]</sup>. An alteration in phagocyte function is the main mission of *H. pylori* to facilitate persistent infection. Therefore, there are undoubtedly other mechanisms involved in the persistence of *H. pylori* against phagocytosis<sup>[95,96]</sup>. Further *in vitro* and *in vivo* experiments are necessary to fully elucidate the complex interactions in chronic *H. pylori* infection.

## ADAPTIVE IMMUNITY

A successful pathogenic organism which aims to overcome innate immunity to establish colonization in an ecological niche leading to chronic infection should possess strategies to overcome adaptive immunity. *H. pylori* modulates adaptive immunity by affecting T

reg and T cell proliferation<sup>[97,98]</sup>. In the next paragraph, we describe the major reactions of *H. pylori* to adaptive immunity which include: (1) enhanced T and B cell functions; and (2) interference in the antigen presentation process.

## EFFECTS ON B AND T CELLS AND THEIR PROLIFERATION

Recent data have demonstrated that *H. pylori* can modulate T cell responses<sup>[99-102]</sup>. Elegant *in vivo* experiments suggested that CD4 T lymphocytes are highly involved in the adaptive immune response against *H. pylori*, in contrast to the relatively inactive role of CD8 T cells. As shown previously, *H. pylori* stimulates the immune response using Th1<sup>[101,103]</sup>. The main interference due to *H. pylori* in the adaptive immune response is its inhibitory effect on T cell proliferation *via* three mechanisms: (1) binding the VacA toxin to the unknown surface ligand in T cells which results in actin rearrangement and then inhibition of cell proliferation<sup>[74,103]</sup>; (2) the VacA toxin is able to form an anion-selective channel in the host cell membrane. These specific channels can cause vacuoles in host cells leading to apoptosis<sup>[104]</sup>. This event starts following attachment of VacA to surface receptor alpha (RPTPα)<sup>[105]</sup>; and (3) VacA can bind to mitochondria and trigger the associated apoptotic pathway. This mechanism can induce inhibition of T cell proliferation. Moreover, VacA located in the membrane of anionic channels inhibits the release of cytochrome C, indicating the crucial role of channel formation in apoptosis induced by *H. pylori* VacA. The exact apoptotic role of VacA needs to be elucidated in the future. We noted that the antibody response is not sufficient to eliminate *H. pylori* infection in humans, as the bacterium has developed strategies to protect itself from the effects of antibodies<sup>[106]</sup>. Unfortunately, the data concerning the actual role of any specific bacterial product to inhibit B cell response are lacking although some experiments have shown that Janus kinase (JAK)-STAT (signal transducer and activator of transcription) suppression by CagA may be a major mechanism in reducing effective B cell response<sup>[107]</sup>.

## INTERFERENCE IN THE ANTIGEN PRESENTATION PROCESS

*H. pylori* has adopted various strategies to interrupt accurate antigen presentation in the host, which is the main method of interfering with late endocytic membrane trafficking. Inhibition of APC activation may be the key point in reducing B cell response to colonization of *H. pylori* in humans<sup>[108]</sup>. Inhibition of MHC-class II export to the cell surface is the main reason for impaired antigen presentation in dendritic cells<sup>[109,110]</sup>. In a novel study, the inhibitory effect of CagA on IL3-dependent B cell proliferation was

reported to be *via* the JAK-STAT signaling pathway, which can cause ineffective antibody secretion in humans<sup>[111,112]</sup>. JAK/STAT signaling is an important immune signaling pathway. Certain inflammatory molecules can activate different types of JAK and STAT. Phosphorylated STAT generates dimers that translocate to the nucleus, thereafter its binding to the promoter of specific genes involved in immune inflammatory response can be stimulated<sup>[112,113]</sup>. As mentioned previously, data regarding the actual role of *H. pylori* in limiting B cell response are scarce and more detailed studies are required to elucidate the complex mechanism responsible for the establishment of persistent infection<sup>[114]</sup>.

## SUBVERSION OF PATTERN RECOGNITION

Different Toll-like receptors (TLRs) corresponding to microbial components called pathogen-associated microbial patterns (PAMPs) are the main components which provide a new strategy for *H. pylori* to avoid involvement with the human immune system. Any interruption of this complex process can hamper bacterial clearance by the immune system. We now know that successful recognition of pathogens by TLRs is involved in both the innate and adaptive systems<sup>[115-118]</sup>. Subversion of TLRs is dependent on recognition by *H. pylori* which helps the bacterium to survive in the strongly immune cell-rich gastric microniche<sup>[119-122]</sup>. TLR4-mediated inflammatory response to LPS in *H. pylori* is largely different to other organisms (almost 1000-fold less reactogenic than other Gram negative bacteria)<sup>[123-129]</sup>. Indeed, co-evolution with humans has resulted in a reduction in immunogenic ligands<sup>[130]</sup>. TLR-dependent immune subversion is a strategy that works in both innate and adaptive immune responses to *H. pylori*; therefore, this adopted strategy should have an effect in hiding the bacterium in the human gastric microniche.

## FIFTH STRATEGY: *H. PYLORI* GENETIC DIVERSITY: FACILITATING PERSISTENT INFECTION

The bacterium is relatively competent in DNA uptake from other *H. pylori* strains. The diversity of the *H. pylori* strains even within a single host is impressive<sup>[131]</sup>. *H. pylori* is a highly heterogeneous bacterium with more than 1600 genes<sup>[12,58,68,69]</sup>. *H. pylori* is a highly competent at taking up both environmental DNA and DNA from other *H. pylori* strains. *H. pylori* was identified as being heterogeneous by a large amount of evidence from experiments investigating (1) allelic variation; (2) SNP; (3) genome size; and (4) bacterial recombination<sup>[21,132-134]</sup>. Genetic recombination is a very important factor involved in adaptation of *H.*




Figure 5 Polymorphism of the *cagA* gene reported in various regions of the world.

*pylori* in the human stomach<sup>[135]</sup>. CagA is a classic virulence factor of the bacterium and has been isolated in different regions of the world (Figure 5). It can be seen from this figure that reported polymorphisms can directly affect its clinical importance. *H. pylori* is considered to be a genetically diverse organism infecting individuals around the world<sup>[19]</sup>. Its high potential for DNA uptake results in *H. pylori* having one of highest recombination rates reported in human pathogenic bacteria. This high rate of recombination causes high genomic variability among the bacterial strains<sup>[134]</sup>. Due to natural selection after these genetic changes, *H. pylori* is more persistent in the gastric microniche. However, it should be mentioned that in addition to genetic recombination, bacterial mutation can have a role in generating highly variable strains observed in persistent infections<sup>[136]</sup>. Almost 10% of its genome consists of specific genes for *H. pylori*<sup>[12]</sup>. Scientists have suggested that chronic persistent infection cannot occur independently. Comparative analyses of full genome sequences of *H. pylori* strains J99 and 26695 in addition to the large amount of data on new sequencing techniques provide new insight into bacterial diversity and its potential to infect humans life-long<sup>[137]</sup>. The *H. pylori* genome is not diverse, but various changes in the third base of codons has resulted in specific strains called "quasi-species"<sup>[133,138,139]</sup>. Currently, both antigenic and phase variation contribute to *H. pylori* persistence against immune responses<sup>[140,141]</sup>. Indeed, wide diversification in the *H. pylori* genome increases the chance of survival in the hostile gastric environment. In order to answer a direct question on the possible mechanism of bacterial diversity to establish chronic persistent infection we need to look at the biology of *H. pylori*. Clearly, bacteria such as *H. pylori* which is exposed to the human immune response and PMNs, it is crucial to promote strategies to avoid these unfavorable conditions. Apart from bacteria such as *E. coli* which have a large genome, *H. pylori* has half the genome

of these bacteria. The main genetic deficiency in *H. pylori* is its two-component regulatory system<sup>[142]</sup>. Deficiencies in mismatch-repair systems of *H. pylori* can increase the frequency of genetic variation, and may facilitate minimal genetic diversity. Thus, *H. pylori* can take advantage of diversity in genetic sequences following selective pressure. To compensate for the lack of genetic contents in the regulatory systems, *H. pylori* has adopted the strategy of remaining life-long in the gastric microniche. This strategy means nonstop recombination and genetic change in the genome and then natural selection to choose the fittest organisms to adapt and live in the gastric environment. This adaptation can also be translated into successful bacterial immune evasion during *H. pylori* persistence.

## CONCLUSION

The beginning of the *H. pylori* era in 1984 was characterized by questions which require considerable attention; such as treatment, efficient vaccines, useful biomarkers and management of the infection<sup>[6,31,143]</sup>. For *H. pylori*, similar to most common gastric pathogens, we have information on its many molecular mechanisms, but its survival strategies in the human host are not well elucidated. The human stomach is a challenging niche for bacterial colonization; therefore, sophisticated strategies to aid survival of the bacterium would not be surprising. Bacterial genetic diversity and extensive polymorphism also facilitate the survival of *H. pylori* within the hostile gastric environment<sup>[14,63,144]</sup>. The potential for *H. pylori* to survive in the strong acidic conditions in the stomach is considered a major feature of bacterial persistence. Even with the five strategies described in this study, there is a big gap in the knowledge concerning the mechanisms involved in the persistent colonization of *H. pylori*. Initially, a useful buffering potential in addition to the presence of sufficient bacterial adhesion facilitate primary colonization and then continuous genetic diversification



in parallel with immune evasion are the main strategies used for persistent infection. Despite intensive studies, the molecular host - *H. pylori* interactions, particularly in symptomatic patients colonized by persistent *H. pylori* are obscure. Understanding the details of *H. pylori* persistence and its contributing elements will help identify better strategies to treat the infection or may design better drug targets.

## ACKNOWLEDGMENTS

The content of this review article is the sole responsibility of the author and necessarily represents a personal prospective. Moreover, the funding agencies had no role in the decision to publish, or preparation of the manuscript.

## REFERENCES

- 1 Abadi ATB, Ierardi E, Lee YY. Why do we still have Helicobacter Pylori in our Stomachs? *Malays J Med Sci* 2015; **22**: 70-75
- 2 Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, Falush D, Stamer C, Prugnolle F, van der Merwe SW, Yamaoka Y, Graham DY, Perez-Trallero E, Wadstrom T, Suerbaum S, Achtman M. An African origin for the intimate association between humans and Helicobacter pylori. *Nature* 2007; **445**: 915-918 [PMID: 17287725 DOI: 10.1038/nature05562]
- 3 Schlebusch CM, Skoglund P, Sjödin P, Gattepaille LM, Hernandez D, Jay F, Li S, De Jongh M, Singleton A, Blum MG, Soodyall H, Jakobsson M. Genomic variation in seven Khoe-San groups reveals adaptation and complex African history. *Science* 2012; **338**: 374-379 [PMID: 22997136 DOI: 10.1126/science.1227721]
- 4 Didelot X, Nell S, Yang I, Woltemate S, van der Merwe S, Suerbaum S. Genomic evolution and transmission of Helicobacter pylori in two South African families. *Proc Natl Acad Sci USA* 2013; **110**: 13880-13885 [PMID: 23898187 DOI: 10.1073/pnas.1304681110]
- 5 Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. *J Clin Invest* 2009; **119**: 2475-2487 [PMID: 19729845 DOI: 10.1172/JCI38605]
- 6 Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev* 2006; **19**: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]
- 7 Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; **16**: 167-180 [PMID: 11860399]
- 8 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
- 9 Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
- 10 Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]
- 11 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. *J Glob Antimicrob Resist* 2017; **8**: 123-130 [PMID: 28131855 DOI: 10.1016/j.jgar.2016.11.008]
- 12 Yamaoka Y. Pathogenesis of Helicobacter pylori-Related Gastrointestinal Diseases from Molecular Epidemiological Studies. *Gastroenterol Res Pract* 2012; **2012**: 371503 [PMID: 22829807 DOI: 10.1155/2012/371503]
- 13 Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. *Helicobacter* 2010; **15** Suppl 1: 14-20 [PMID: 21054648 DOI: 10.1111/j.1523-5378.2010.00781.x]
- 14 Abadi AT, Kusters JG. Management of Helicobacter pylori infections. *BMC Gastroenterol* 2016; **16**: 94 [PMID: 27520775 DOI: 10.1186/s12876-016-0496-2]
- 15 Fischer F, Robbe-Saule M, Turlin E, Mancuso F, Michel V, Richaud P, Veyrier FJ, De Reuse H, Vinella D. Characterization in Helicobacter pylori of a Nickel Transporter Essential for Colonization That Was Acquired during Evolution by Gastric Helicobacter Species. *PLoS Pathog* 2016; **12**: e1006018 [PMID: 27923069 DOI: 10.1371/journal.ppat.1006018]
- 16 Wen Y, Marcus EA, Matrubutham U, Gleeson MA, Scott DR, Sachs G. Acid-adaptive genes of Helicobacter pylori. *Infect Immun* 2003; **71**: 5921-5939 [PMID: 14500513]
- 17 Robinson K, Letley DP, Kaneko K. The Human Stomach in Health and Disease: Infection Strategies by Helicobacter pylori. *Curr Top Microbiol Immunol* 2017; **400**: 1-26 [PMID: 28124147 DOI: 10.1007/978-3-319-50520-6\_1]
- 18 Marcus EA, Scott DR. Gastric Colonization by H. pylori. Springer, 2016: 23-34
- 19 Israel DA, Peek RM. The role of persistence in Helicobacter pylori pathogenesis. *Curr Opin Gastroenterol* 2006; **22**: 3-7 [PMID: 16319669]
- 20 van Vliet AH. Use of pan-genome analysis for the identification of lineage-specific genes of Helicobacter pylori. *FEMS Microbiol Lett* 2017; **364**: [PMID: 28011701 DOI: 10.1093/femsle/fnw296]
- 21 Sachs G, Wen Y, Scott DR. Gastric infection by Helicobacter pylori. *Curr Gastroenterol Rep* 2009; **11**: 455-461 [PMID: 19903421]
- 22 Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of Helicobacter pylori urease and catalase at low pH. *Gut* 1997; **40**: 25-30 [PMID: 9155571]
- 23 Stingl K, De Reuse H. Staying alive overdosed: how does Helicobacter pylori control urease activity? *Int J Med Microbiol* 2005; **295**: 307-315 [PMID: 16173497 DOI: 10.1016/j.ijmm.2005.06.006]
- 24 Huang JY, Goers Sweeney E, Guillemin K, Amieva MR. Multiple Acid Sensors Control Helicobacter pylori Colonization of the Stomach. *PLoS Pathog* 2017; **13**: e1006118 [PMID: 28103315 DOI: 10.1371/journal.ppat.1006118]
- 25 Kao CY, Sheu BS, Wu JJ. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. *Biomed J* 2016; **39**: 14-23 [PMID: 27105595 DOI: 10.1016/j.bj.2015.06.002]
- 26 Marcus EA, Sachs G, Wen Y, Scott DR. Phosphorylation-dependent and Phosphorylation-independent Regulation of Helicobacter pylori Acid Acclimation by the ArsRS Two-component System. *Helicobacter* 2016; **21**: 69-81 [PMID: 25997502 DOI: 10.1111/hel.12235]
- 27 Servetas SL, Carpenter BM, Haley KP, Gilbreath JJ, Gaddy JA, Merrell DS. Characterization of Key Helicobacter pylori Regulators Identifies a Role for ArsRS in Biofilm Formation. *J Bacteriol* 2016; **198**: 2536-2548 [PMID: 27432830 DOI: 10.1128/JB.00324-16]
- 28 Carpenter BM, West AL, Gancz H, Servetas SL, Pich OQ, Gilbreath JJ, Hallinger DR, Forsyth MH, Merrell DS, Michel SL. Crosstalk between the HpArsRS two-component system and HpNikR is necessary for maximal activation of urease transcription. *Front Microbiol* 2015; **6**: 558 [PMID: 26124751 DOI: 10.3389/fmicb.2015.00558]
- 29 Scott DR, Marcus EA, Wen Y, Oh J, Sachs G. Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface. *Proc Natl Acad Sci USA* 2007; **104**: 7235-7240 [PMID: 17438279 DOI: 10.1073/pnas.0702300104]
- 30 Krishna U, Romero-Gallo J, Suarez G, Azah A, Krezel AM, Varga MG, Forsyth MH, Peek RM. Genetic Evolution of a Helicobacter



- pylori* Acid-Sensing Histidine Kinase and Gastric Disease. *J Infect Dis* 2016; **214**: 644-648 [PMID: 27190191 DOI: 10.1093/infdis/jiw189]
- 31 **Talebi Bezmin Abadi A.** *Helicobacter pylori* and Gastric Cancer. *Front Med (Lausanne)* 2016; **3**: 36 [PMID: 27597945 DOI: 10.3389/fmed.2016.00036]
  - 32 **Talebi Bezmin Abadi A.** *Helicobacter pylori*: Emergence of a Superbug. *Front Med (Lausanne)* 2014; **1**: 34 [PMID: 25593908 DOI: 10.3389/fmed.2014.00034]
  - 33 **Dudley J, Wiczorek T, Selig M, Cheung H, Shen J, Odze R, Deshpande V, Zukerberg L.** Clinicopathological characteristics of invasive gastric *Helicobacter pylori*. *Hum Pathol* 2017; **61**: 19-25 [10.1016/j.humpath.2016.09.029]
  - 34 **Backert S, Schmidt TP, Harrer A, Wessler S.** Exploiting the Gastric Epithelial Barrier: *Helicobacter pylori*'s Attack on Tight and Adherens Junctions. *Curr Top Microbiol Immunol* 2017; **400**: 195-226 [PMID: 28124155 DOI: 10.1007/978-3-319-50520-6\_9]
  - 35 **Huang Y, Wang QL, Cheng DD, Xu WT, Lu NH.** Adhesion and Invasion of Gastric Mucosa Epithelial Cells by *Helicobacter pylori*. *Front Cell Infect Microbiol* 2016; **6**: 159 [PMID: 27921009 DOI: 10.3389/fcimb.2016.00159]
  - 36 **Amieva MR, Salama NR, Tompkins LS, Falkow S.** *Helicobacter pylori* enter and survive within multivesicular vacuoles of epithelial cells. *Cell Microbiol* 2002; **4**: 677-690 [PMID: 12366404]
  - 37 **Deen NS, Huang SJ, Gong L, Kwok T, Devenish RJ.** The impact of autophagic processes on the intracellular fate of *Helicobacter pylori*: more tricks from an enigmatic pathogen? *Autophagy* 2013; **9**: 639-652 [PMID: 23396129 DOI: 10.4161/auto.23782]
  - 38 **Borén T, Falk P, Roth KA, Larson G, Normark S.** Attachment of *Helicobacter pylori* to human gastric epithelium mediated by blood group antigens. *Science* 1993; **262**: 1892-1895 [PMID: 8018146]
  - 39 **Talebi Bezmin Abadi A, Taghvaei T, Mohabbati Mobarez A, Vaira G, Vaira D.** High correlation of babA 2-positive strains of *Helicobacter pylori* with the presence of gastric cancer. *Intern Emerg Med* 2013; **8**: 497-501 [PMID: 21604199 DOI: 10.1007/s11739-011-0631-6]
  - 40 **Appelmek BJ, Monteiro MA, Martin SL, Moran AP, Vandenbroucke-Grauls CM.** Why *Helicobacter pylori* has Lewis antigens. *Trends Microbiol* 2000; **8**: 565-570 [PMID: 11115753]
  - 41 **Edwards NJ, Monteiro MA, Faller G, Walsh EJ, Moran AP, Roberts IS, High NJ.** Lewis X structures in the O antigen side-chain promote adhesion of *Helicobacter pylori* to the gastric epithelium. *Mol Microbiol* 2000; **35**: 1530-1539 [PMID: 10760152]
  - 42 **Valkonen KH, Wadström T, Moran AP.** Identification of the N-acetylneuraminylactose-specific laminin-binding protein of *Helicobacter pylori*. *Infect Immun* 1997; **65**: 916-923 [PMID: 9038297]
  - 43 **Kavermann H, Burns BP, Angermüller K, Odenbreit S, Fischer W, Melchers K, Haas R.** Identification and characterization of *Helicobacter pylori* genes essential for gastric colonization. *J Exp Med* 2003; **197**: 813-822 [PMID: 12668646 DOI: 10.1084/jem.20021531]
  - 44 **Selbach M, Moese S, Hurwitz R, Hauck CR, Meyer TF, Backert S.** The *Helicobacter pylori* CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. *EMBO J* 2003; **22**: 515-528 [PMID: 12554652 DOI: 10.1093/emboj/cdg050]
  - 45 **Oleastro M, Ménard A.** The Role of *Helicobacter pylori* Outer Membrane Proteins in Adherence and Pathogenesis. *Biology (Basel)* 2013; **2**: 1110-1134 [PMID: 24833057 DOI: 10.3390/biology2031110]
  - 46 **Talebi Bezmin Abadi A, Perez-Perez G.** Role of dupA in virulence of *Helicobacter pylori*. *World J Gastroenterol* 2016; **22**: 10118-10123 [PMID: 28028359 DOI: 10.3748/wjg.v22.i46.10118]
  - 47 **Churin Y, Al-Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M.** *Helicobacter pylori* CagA protein targets the c-Met receptor and enhances the mitogenic response. *J Cell Biol* 2003; **161**: 249-255 [PMID: 12719469 DOI: 10.1083/jcb.200208039]
  - 48 **Sycuro LK, Pincus Z, Gutierrez KD, Biboy J, Stern CA, Vollmer W, Salama NR.** Peptidoglycan crosslinking relaxation promotes *Helicobacter pylori*'s helical shape and stomach colonization. *Cell* 2010; **141**: 822-833 [PMID: 20510929 DOI: 10.1016/j.cell.2010.03.046]
  - 49 **Bansil R, Celli JP, Hardcastle JM, Turner BS.** The Influence of Mucus Microstructure and Rheology in *Helicobacter pylori* Infection. *Front Immunol* 2013; **4**: 310 [PMID: 24133493 DOI: 10.3389/fimmu.2013.00310]
  - 50 **Sycuro LK, Rule CS, Petersen TW, Wyckoff TJ, Sessler T, Nagarkar DB, Khalid F, Pincus Z, Biboy J, Vollmer W, Salama NR.** Flow cytometry-based enrichment for cell shape mutants identifies multiple genes that influence *Helicobacter pylori* morphology. *Mol Microbiol* 2013; **90**: 869-883 [PMID: 24112477 DOI: 10.1111/mmi.12405]
  - 51 **Kim JS, Chang JH, Chung SI, Yum JS.** Molecular cloning and characterization of the *Helicobacter pylori* fliD gene, an essential factor in flagellar structure and motility. *J Bacteriol* 1999; **181**: 6969-6976 [PMID: 10559162]
  - 52 **Celli JP, Turner BS, Afdhal NH, Ewoldt RH, McKinley GH, Bansil R, Erramilli S.** Rheology of gastric mucin exhibits a pH-dependent sol-gel transition. *Biomacromolecules* 2007; **8**: 1580-1586 [PMID: 17402780 DOI: 10.1021/bm0609691]
  - 53 **Ottmann KM, Lowenthal AC.** *Helicobacter pylori* uses motility for initial colonization and to attain robust infection. *Infect Immun* 2002; **70**: 1984-1990 [PMID: 11895962]
  - 54 **Schoenhofen IC, Lunin VV, Julien JP, Li Y, Ajamian E, Matte A, Cygler M, Brisson JR, Aubry A, Logan SM, Bhatia S, Wakarchuk WW, Young NM.** Structural and functional characterization of PseC, an aminotransferase involved in the biosynthesis of pseudaminic acid, an essential flagellar modification in *Helicobacter pylori*. *J Biol Chem* 2006; **281**: 8907-8916 [PMID: 16421095 DOI: 10.1074/jbc.M512987200]
  - 55 **Rhee KH, Park JS, Cho MJ.** *Helicobacter pylori*: bacterial strategy for incipient stage and persistent colonization in human gastric niches. *Yonsei Med J* 2014; **55**: 1453-1466 [PMID: 25323880 DOI: 10.3349/ymj.2014.55.6.1453]
  - 56 **McGowan CC, Cover TL, Blaser MJ.** *Helicobacter pylori* and gastric acid: biological and therapeutic implications. *Gastroenterology* 1996; **110**: 926-938 [PMID: 8608904]
  - 57 **Robinson K, Argent RH, Atherton JC.** The inflammatory and immune response to *Helicobacter pylori* infection. *Best Pract Res Clin Gastroenterol* 2007; **21**: 237-259 [PMID: 17382275 DOI: 10.1016/j.bpg.2007.01.001]
  - 58 **Baldari CT, Lanzavecchia A, Telford JL.** Immune subversion by *Helicobacter pylori*. *Trends Immunol* 2005; **26**: 199-207 [PMID: 15797510 DOI: 10.1016/j.it.2005.01.007]
  - 59 **Blaser MJ, Berg DE.** *Helicobacter pylori* genetic diversity and risk of human disease. *J Clin Invest* 2001; **107**: 767-773 [PMID: 11285290 DOI: 10.1172/JCI12672]
  - 60 **Graham DY.** History of *Helicobacter pylori*, duodenal ulcer, gastric ulcer and gastric cancer. *World J Gastroenterol* 2014; **20**: 5191-5204 [PMID: 24833849 DOI: 10.3748/wjg.v20.i18.5191]
  - 61 **Müller A, Solnick JV.** Inflammation, immunity, and vaccine development for *Helicobacter pylori*. *Helicobacter* 2011; **16** Suppl 1: 26-32 [PMID: 21896082 DOI: 10.1111/j.1523-5378.2011.00877.x]
  - 62 **Blaser MJ, Atherton JC.** *Helicobacter pylori* persistence: biology and disease. *J Clin Invest* 2004; **113**: 321-333 [PMID: 14755326 DOI: 10.1172/JCI20925]
  - 63 **Backert S, Neddermann M, Maubach G, Naumann M.** Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2016; **21** Suppl 1: 19-25 [PMID: 27531534 DOI: 10.1111/hel.12335]
  - 64 **Mejias-Luqu R, Gerhard M.** Immune Evasion Strategies and Persistence of *Helicobacter pylori*. Molecular Pathogenesis and Signal Transduction by *Helicobacter pylori*. Springer, 2017: 53-71
  - 65 **Wunder C, Churin Y, Winau F, Warnecke D, Vieth M, Lindner B, Zähringer U, Mollenkopf HJ, Heinz E, Meyer TF.** Cholesterol glucosylation promotes immune evasion by *Helicobacter pylori*. *Nat Med* 2006; **12**: 1030-1038 [PMID: 16951684 DOI: 10.1038/nm1480]
  - 66 **Aebischer T, Laforsch S, Hurwitz R, Brombacher F, Meyer TF.** Immunity against *Helicobacter pylori*: significance of interleukin-4

- receptor alpha chain status and gender of infected mice. *Infect Immun* 2001; **69**: 556-558 [PMID: 11119552 DOI: 10.1128/IAI.69.1.556-558.2001]
- 67 **Crabtree JE**. Immune and inflammatory responses to *Helicobacter pylori* infection. *Scand J Gastroenterol Suppl* 1996; **215**: 3-10 [PMID: 8722376]
  - 68 **D'Elia MM**, Andersen LP. *Helicobacter pylori* inflammation, immunity, and vaccines. *Helicobacter* 2007; **12** Suppl 1: 15-19 [PMID: 17727455 DOI: 10.1111/j.1523-5378.2007.00530.x]
  - 69 **Michetti P**, Svennerholm AM. *Helicobacter pylori*-inflammation, immunity and vaccines. *Helicobacter* 2003; **8** Suppl 1: 31-35 [PMID: 14617215]
  - 70 **Allen LA**. The role of the neutrophil and phagocytosis in infection caused by *Helicobacter pylori*. *Curr Opin Infect Dis* 2001; **14**: 273-277 [PMID: 11964843]
  - 71 **Allen LA**. Phagocytosis and persistence of *Helicobacter pylori*. *Cell Microbiol* 2007; **9**: 817-828 [PMID: 17346311 DOI: 10.1111/j.1462-5822.2007.00906.x]
  - 72 **Allen LA**. Rate and extent of *Helicobacter pylori* phagocytosis. *Methods Mol Biol* 2008; **431**: 147-157 [PMID: 18287754]
  - 73 **Deen NS**, Gong L, Naderer T, Devenish RJ, Kwok T. Analysis of the Relative Contribution of Phagocytosis, LC3-Associated Phagocytosis, and Canonical Autophagy During *Helicobacter pylori* Infection of Macrophages. *Helicobacter* 2015; **20**: 449-459 [PMID: 25864465 DOI: 10.1111/hel.12223]
  - 74 **Abadi AT**, Lee YY. *Helicobacter pylori* vacA as marker for gastric cancer and gastroduodenal diseases: one but not the only factor. *J Clin Microbiol* 2014; **52**: 4451 [PMID: 25399000 DOI: 10.1128/JCM.02640-14]
  - 75 **Blaser MJ**. *Helicobacter pylori* and the pathogenesis of gastroduodenal inflammation. *J Infect Dis* 1990; **161**: 626-633 [PMID: 2181029]
  - 76 **Ramarao N**, Meyer TF. *Helicobacter pylori* resists phagocytosis by macrophages: quantitative assessment by confocal microscopy and fluorescence-activated cell sorting. *Infect Immun* 2001; **69**: 2604-2611 [PMID: 11254625 DOI: 10.1128/IAI.69.4.2604-2611.2001]
  - 77 **Demiray E**, Bekmen N. [*Helicobacter pylori* infection and phagocytosis]. *Mikrobiyol Bul* 2008; **42**: 177-184 [PMID: 18444577]
  - 78 **Nazligul Y**, Aslan M, Horoz M, Celik Y, Dulger AC, Celik H, Erel O. The effect on serum myeloperoxidase activity and oxidative status of eradication treatment in patients *Helicobacter pylori* infected. *Clin Biochem* 2011; **44**: 647-649 [PMID: 21396358 DOI: 10.1016/j.clinbiochem.2011.03.001]
  - 79 **Borlace GN**, Butler RN, Brooks DA. Monocyte and macrophage killing of *Helicobacter pylori*: relationship to bacterial virulence factors. *Helicobacter* 2008; **13**: 380-387 [PMID: 19250513 DOI: 10.1111/j.1523-5378.2008.00625.x]
  - 80 **Calvino-Fernández M**, Benito-Martínez S, Parra-Cid T. Oxidative stress by *Helicobacter pylori* causes apoptosis through mitochondrial pathway in gastric epithelial cells. *Apoptosis* 2008; **13**: 1267-1280 [PMID: 18766443 DOI: 10.1007/s10495-008-0255-0]
  - 81 **Chaturvedi R**, Cheng Y, Asim M, Bussière FI, Xu H, Gobert AP, Hacker A, Casero RA, Wilson KT. Induction of polyamine oxidase 1 by *Helicobacter pylori* causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. *J Biol Chem* 2004; **279**: 40161-40173 [PMID: 15247269 DOI: 10.1074/jbc.M401370200]
  - 82 **Cross RK**, Wilson KT. Nitric oxide in inflammatory bowel disease. *Inflamm Bowel Dis* 2003; **9**: 179-189 [PMID: 12792224]
  - 83 **Lundström AM**, Sundaeus V, Bölin I. The 26-kilodalton, AhpC homologue, of *Helicobacter pylori* is also produced by other *Helicobacter* species. *Helicobacter* 2001; **6**: 44-54 [PMID: 11328365]
  - 84 **Papinutto E**, Windle HJ, Cendron L, Battistutta R, Kelleher D, Zanotti G. Crystal structure of alkyl hydroperoxide-reductase (AhpC) from *Helicobacter pylori*. *Biochim Biophys Acta* 2005; **1753**: 240-246 [PMID: 16213196 DOI: 10.1016/j.bbapap.2005.09.001]
  - 85 **Zhang B**, Li HL, Fan Q, Guo F, Ren XY, Zhou HB, Zhu JW, Zhao YS, Tian WJ. Serum *Helicobacter pylori* KatA and AhpC antibodies as novel biomarkers for gastric cancer. *World J Gastroenterol* 2016; **22**: 5060-5067 [PMID: 27275098 DOI: 10.3748/wjg.v22.i21.5060]
  - 86 **Augusto AC**, Miguel F, Mendonça S, Pedrazzoli J, Gurgueira SA. Oxidative stress expression status associated to *Helicobacter pylori* virulence in gastric diseases. *Clin Biochem* 2007; **40**: 615-622 [PMID: 17466292 DOI: 10.1016/j.clinbiochem.2007.03.014]
  - 87 **Gobert AP**, Cheng Y, Wang JY, Boucher JL, Iyer RK, Cederbaum SD, Casero RA, Newton JC, Wilson KT. *Helicobacter pylori* induces macrophage apoptosis by activation of arginase II. *J Immunol* 2002; **168**: 4692-4700 [PMID: 11971019]
  - 88 **El Kasmi KC**, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M, Basaraba RJ, König T, Schleicher U, Koo MS, Kaplan G, Fitzgerald KA, Tuomanen EI, Orme IM, Kanneganti TD, Bogdan C, Wynn TA, Murray PJ. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. *Nat Immunol* 2008; **9**: 1399-1406 [PMID: 18978793 DOI: 10.1038/ni.1671]
  - 89 **Wilson KT**, Crabtree JE. Immunology of *Helicobacter pylori*: insights into the failure of the immune response and perspectives on vaccine studies. *Gastroenterology* 2007; **133**: 288-308 [PMID: 17631150 DOI: 10.1053/j.gastro.2007.05.008]
  - 90 **Gobert AP**, McGee DJ, Akhtar M, Mendz GL, Newton JC, Cheng Y, Mobley HL, Wilson KT. *Helicobacter pylori* arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. *Proc Natl Acad Sci USA* 2001; **98**: 13844-13849 [PMID: 11717441 DOI: 10.1073/pnas.241443798]
  - 91 **Rogers PA**, Eide L, Klungland A, Ding H. Reversible inactivation of E. coli endonuclease III via modification of its [4Fe-4S] cluster by nitric oxide. *DNA Repair (Amst)* 2003; **2**: 809-817 [PMID: 12826281]
  - 92 **Rittig MG**, Shaw B, Letley DP, Thomas RJ, Argent RH, Atherton JC. *Helicobacter pylori*-induced homotypic phagosome fusion in human monocytes is independent of the bacterial vacA and cag status. *Cell Microbiol* 2003; **5**: 887-899 [PMID: 14641174]
  - 93 **Zheng PY**, Jones NL. *Helicobacter pylori* strains expressing the vacuolating cytotoxin interrupt phagosome maturation in macrophages by recruiting and retaining TACO (coronin 1) protein. *Cell Microbiol* 2003; **5**: 25-40 [PMID: 12542468]
  - 94 **Borody T**, Ren Z, Pang G, Clancy R. Impaired host immunity contributes to *Helicobacter pylori* eradication failure. *Am J Gastroenterol* 2002; **97**: 3032-3037 [PMID: 12492186 DOI: 10.1111/j.1572-0241.2002.07121.x]
  - 95 **Del Giudice G**, Michetti P. Inflammation, immunity and vaccines for *Helicobacter pylori*. *Helicobacter* 2004; **9** Suppl 1: 23-28 [PMID: 15347302 DOI: 10.1111/j.1083-4389.2004.00245.x]
  - 96 **Permin H**, Andersen LP. Inflammation, immunity, and vaccines for *Helicobacter* infection. *Helicobacter* 2005; **10** Suppl 1: 21-25 [PMID: 16178967 DOI: 10.1111/j.1523-5378.2005.00337.x]
  - 97 **Raghavan S**, Quiding-Järbrink M. Immune modulation by regulatory T cells in *Helicobacter pylori*-associated diseases. *Endocr Metab Immune Disord Drug Targets* 2012; **12**: 71-85 [PMID: 22214337]
  - 98 **Gray BM**, Fontaine CA, Poe SA, Eaton KA. Complex T cell interactions contribute to *Helicobacter pylori* gastritis in mice. *Infect Immun* 2013; **81**: 740-752 [PMID: 23264048 DOI: 10.1128/IAI.01269-12]
  - 99 **Ermak TH**, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP. Immunization of mice with urease vaccine affords protection against *Helicobacter pylori* infection in the absence of antibodies and is mediated by MHC class II-restricted responses. *J Exp Med* 1998; **188**: 2277-2288 [PMID: 9858514]
  - 100 **Thamphiwatana S**, Gao W, Obonyo M, Zhang L. In vivo treatment of *Helicobacter pylori* infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. *Proc Natl Acad Sci USA* 2014; **111**: 17600-17605 [PMID: 25422427 DOI: 10.1073/pnas.1418230111]

- 101 **Ding H**, Nedrud JG, Blanchard TG, Zagorski BM, Li G, Shiu J, Xu J, Czinn SJ. Th1-mediated immunity against *Helicobacter pylori* can compensate for lack of Th17 cells and can protect mice in the absence of immunization. *PLoS One* 2013; **8**: e69384 [PMID: 23874957 DOI: 10.1371/journal.pone.0069384]
- 102 **Beigier-Bompadre M**, Moos V, Belogolova E, Allers K, Schneider T, Churin Y, Ignatius R, Meyer TF, Aebischer T. Modulation of the CD4+ T-cell response by *Helicobacter pylori* depends on known virulence factors and bacterial cholesterol and cholesterol  $\alpha$ -glucoside content. *J Infect Dis* 2011; **204**: 1339-1348 [PMID: 21921201 DOI: 10.1093/infdis/jir547]
- 103 **Ernst PB**, Pappo J. T-cell-mediated mucosal immunity in the absence of antibody: lessons from *Helicobacter pylori* infection. *Acta Odontol Scand* 2001; **59**: 216-221 [PMID: 11570524]
- 104 **Yahiro K**, Akazawa Y, Nakano M, Suzuki H, Hisatune J, Isomoto H, Sap J, Noda M, Moss J, Hirayama T. *Helicobacter pylori* VacA induces apoptosis by accumulation of connexin 43 in autophagic vesicles via a Rac1/ERK-dependent pathway. *Cell Death Discov* 2015; **1**: 15035 [PMID: 27551466 DOI: 10.1038/cddiscovery.2015.35]
- 105 **Radin JN**, González-Rivera C, Frick-Cheng AE, Sheng J, Gaddy JA, Rubin DH, Algood HM, McClain MS, Cover TL. Role of connexin 43 in *Helicobacter pylori* VacA-induced cell death. *Infect Immun* 2014; **82**: 423-432 [PMID: 24191302 DOI: 10.1128/IAI.00827-13]
- 106 **Yokota Si**, Amano Ki, Hayashi S, Kubota T, Fujii N, Yokochi T. Human antibody response to *Helicobacter pylori* lipopolysaccharide: presence of an immunodominant epitope in the polysaccharide chain of lipopolysaccharide. *Infect Immun* 1998; **66**: 3006-3011 [PMID: 9596783]
- 107 **Yu H**, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 2009; **9**: 798-809 [PMID: 19851315 DOI: 10.1038/nrc2734]
- 108 **Engstrand L**, Gustavsson S, Schwan A, Scheynius A. Local and systemic immune response in *Helicobacter pylori*-associated chronic gastritis before and after treatment. *Scand J Gastroenterol* 1993; **28**: 1105-1111 [PMID: 7905661]
- 109 **Wang YH**, Gorvel JP, Chu YT, Wu JJ, Lei HY. *Helicobacter pylori* impairs murine dendritic cell responses to infection. *PLoS One* 2010; **5**: e10844 [PMID: 20523725 DOI: 10.1371/journal.pone.0010844]
- 110 **Kranzer K**, Eckhardt A, Aigner M, Knoll G, Deml L, Speth C, Lehn N, Rehli M, Schneider-Brachert W. Induction of maturation and cytokine release of human dendritic cells by *Helicobacter pylori*. *Infect Immun* 2004; **72**: 4416-4423 [PMID: 15271898 DOI: 10.1128/IAI.72.8.4416-4423.2004]
- 111 **Umehara S**, Higashi H, Ohnishi N, Asaka M, Hatakeyama M. Effects of *Helicobacter pylori* CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma. *Oncogene* 2003; **22**: 8337-8342 [PMID: 14614457 DOI: 10.1038/sj.onc.1207028]
- 112 **Leonard WJ**. The Jak-STAT pathway. *Hormone Signaling* 2002; **7**: 103-120
- 113 **Igaz P**, Tóth S, Falus A. Biological and clinical significance of the JAK-STAT pathway: lessons from knockout mice. *Inflamm Res* 2001; **50**: 435-441 [PMID: 11603847 DOI: 10.1007/PL00000267]
- 114 **Kim N**. Immunological Reactions on *H. pylori* Infection. *Helicobacter pylori*: Springer, 2016: 35-52 [DOI: 10.1007/978-981-287-706-2\_3]
- 115 **West AC**, Jenkins BJ. Investigating the Role of Toll-Like Receptors in Mouse Models of Gastric Cancer. *Methods Mol Biol* 2016; **1390**: 427-449 [PMID: 26803643 DOI: 10.1007/978-1-4939-3335-8\_25]
- 116 **Hammond CE**, Beeson C, Suarez G, Peek RM, Backert S, Smolka AJ. *Helicobacter pylori* virulence factors affecting gastric proton pump expression and acid secretion. *Am J Physiol Gastrointest Liver Physiol* 2015; **309**: G193-G201 [PMID: 26045613 DOI: 10.1152/ajpgi.00099.2015]
- 117 **Hossain MJ**, Tanasescu R, Gran B. Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2. *J Neuroimmunol* 2017; **304**: 11-20 [PMID: 28007303 DOI: 10.1016/j.jneuroim.2016.12.004]
- 118 **Hu Y**, Liu JP, Zhu Y, Lu NH. The Importance of Toll-like Receptors in NF- $\kappa$ B Signaling Pathway Activation by *Helicobacter pylori* Infection and the Regulators of this Response. *Helicobacter* 2016; **21**: 428-440 [PMID: 26763943 DOI: 10.1111/hel.12292]
- 119 **Djekic A**, Müller A. The Immunomodulator VacA Promotes Immune Tolerance and Persistent *Helicobacter pylori* Infection through Its Activities on T-Cells and Antigen-Presenting Cells. *Toxins* (Basel) 2016; **8**: [PMID: 27322319 DOI: 10.3390/toxins8060187]
- 120 **Kivrak Salim D**, Sahin M, Köksoy S, Adanir H, Süleymanlar I. Local Immune Response in *Helicobacter pylori* Infection. *Medicine* (Baltimore) 2016; **95**: e3713 [PMID: 27196487 DOI: 10.1097/MD.0000000000003713]
- 121 **Sjökvisst Ottsjö L**, Jeverstam F, Yrlid L, Wenzel AU, Walduck AK, Raghavan S. Induction of mucosal immune responses against *Helicobacter pylori* infection after sublingual and intragastric route of immunization. *Immunology* 2017; **150**: 172-183 [PMID: 27676456 DOI: 10.1111/imm.12676]
- 122 **Smith SM**, Freeley M, Moynagh PN, Kelleher DP. Differential modulation of *Helicobacter pylori* lipopolysaccharide-mediated TLR2 signaling by individual Pellino proteins. *Helicobacter* 2017; **22**: [PMID: 27302665 DOI: 10.1111/hel.12325]
- 123 **Mai UE**, Perez-Perez GI, Wahl LM, Wahl SM, Blaser MJ, Smith PD. Soluble surface proteins from *Helicobacter pylori* activate monocytes/macrophages by lipopolysaccharide-independent mechanism. *J Clin Invest* 1991; **87**: 894-900 [PMID: 1847939 DOI: 10.1172/JCI115095]
- 124 **Kidd M**, Miu K, Tang LH, Perez-Perez GI, Blaser MJ, Sandor A, Modlin IM. *Helicobacter pylori* lipopolysaccharide stimulates histamine release and DNA synthesis in rat enterochromaffin-like cells. *Gastroenterology* 1997; **113**: 1110-1117 [PMID: 9322505]
- 125 **Li H**, Liao T, Debowski AW, Tang H, Nilsson HO, Stubbs KA, Marshall BJ, Benghezal M. Lipopolysaccharide Structure and Biosynthesis in *Helicobacter pylori*. *Helicobacter* 2016; **21**: 445-461 [PMID: 26934862 DOI: 10.1111/hel.12301]
- 126 **Pachathundikandi SK**, Müller A, Backert S. Inflammasome Activation by *Helicobacter pylori* and Its Implications for Persistence and Immunity. *Curr Top Microbiol Immunol* 2016; **397**: 117-131 [PMID: 27460807 DOI: 10.1007/978-3-319-41171-2\_6]
- 127 **Naumann M**, Sokolova O, Tegtmeyer N, Backert S. *Helicobacter pylori*: A Paradigm Pathogen for Subverting Host Cell Signal Transduction. *Trends Microbiol* 2017; **25**: 316-328 [PMID: 28057411 DOI: 10.1016/j.tim.2016.12.004]
- 128 **Koch M**, Mollenkopf HJ, Meyer TF. Macrophages recognize the *Helicobacter pylori* type IV secretion system in the absence of toll-like receptor signalling. *Cell Microbiol* 2016; **18**: 137-147 [PMID: 26243717 DOI: 10.1111/cmi.12492]
- 129 **Li S**, Cao M, Song L, Qi P, Chen C, Wang X, Li N, Peng J, Wu D, Hu G, Zhao J. The contribution of toll-like receptor 2 on *Helicobacter pylori* activation of the nuclear factor-kappa B signaling pathway in gastric epithelial cells. *Microb Pathog* 2016; **98**: 63-68 [PMID: 27364547 DOI: 10.1016/j.micpath.2016.06.028]
- 130 **de Jonge R**, Kusters JG, Timmer MS, Gimmel V, Appelmelk BJ, Bereswill S, van Vliet AH, Meuwissen SG, Kist M, Vandenbroucke-Grauls CM, Kuipers EJ. The role of *Helicobacter pylori* virulence factors in interleukin production by monocytic cells. *FEMS Microbiol Lett* 2001; **196**: 235-238 [PMID: 11267785]
- 131 **Salama N**, Guillemin K, McDaniel TK, Sherlock G, Tompkins L, Falkow S. A whole-genome microarray reveals genetic diversity among *Helicobacter pylori* strains. *Proc Natl Acad Sci USA* 2000; **97**: 14668-14673 [PMID: 11121067 DOI: 10.1073/pnas.97.26.14668]
- 132 **Achtman M**, Azuma T, Berg DE, Ito Y, Morelli G, Pan ZJ, Suerbaum S, Thompson SA, van der Ende A, van Doorn LJ. Recombination and clonal groupings within *Helicobacter pylori* from different geographical regions. *Mol Microbiol* 1999; **32**: 459-470 [PMID: 10320570]

- 133 **Suerbaum S**, Josenhans C. Helicobacter pylori evolution and phenotypic diversification in a changing host. *Nat Rev Microbiol* 2007; **5**: 441-452 [PMID: 17505524 DOI: 10.1038/nrmicro1658]
- 134 **Suerbaum S**, Smith JM, Bapumia K, Morelli G, Smith NH, Kunstmann E, Dyrek I, Achtman M. Free recombination within Helicobacter pylori. *Proc Natl Acad Sci USA* 1998; **95**: 12619-12624 [PMID: 9770535]
- 135 **Falush D**, Kraft C, Taylor NS, Correa P, Fox JG, Achtman M, Suerbaum S. Recombination and mutation during long-term gastric colonization by Helicobacter pylori: estimates of clock rates, recombination size, and minimal age. *Proc Natl Acad Sci USA* 2001; **98**: 15056-15061 [PMID: 11742075 DOI: 10.1073/pnas.251396098]
- 136 **Wang G**, Humayun MZ, Taylor DE. Mutation as an origin of genetic variability in Helicobacter pylori. *Trends Microbiol* 1999; **7**: 488-493 [PMID: 10603484]
- 137 **Tomb JF**, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzgerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen Helicobacter pylori. *Nature* 1997; **388**: 539-547 [PMID: 9252185 DOI: 10.1038/41483]
- 138 **Kuipers EJ**, Israel DA, Kusters JG, Gerrits MM, Weel J, van Der Ende A, van Der Hulst RW, Wirth HP, Höök-Nikanne J, Thompson SA, Blaser MJ. Quasispecies development of Helicobacter pylori observed in paired isolates obtained years apart from the same host. *J Infect Dis* 2000; **181**: 273-282 [PMID: 10608776 DOI: 10.1086/315173]
- 139 **Covacci A**, Rappuoli R. Helicobacter pylori: molecular evolution of a bacterial quasi-species. *Curr Opin Microbiol* 1998; **1**: 96-102 [PMID: 10066468]
- 140 **Portal-Celhay C**, Perez-Perez GI. Immune responses to Helicobacter pylori colonization: mechanisms and clinical outcomes. *Clin Sci (Lond)* 2006; **110**: 305-314 [PMID: 16464172 DOI: 10.1042/CS20050232]
- 141 **Bergman M**, Del Prete G, van Kooyk Y, Appelmelk B. Helicobacter pylori phase variation, immune modulation and gastric autoimmunity. *Nat Rev Microbiol* 2006; **4**: 151-159 [PMID: 16415930 DOI: 10.1038/nrmicro1344]
- 142 **Beier D**, Frank R. Molecular characterization of two-component systems of Helicobacter pylori. *J Bacteriol* 2000; **182**: 2068-2076 [PMID: 10735847]
- 143 **Abadi AT**. Vaccine against Helicobacter pylori: Inevitable approach. *World J Gastroenterol* 2016; **22**: 3150-3157 [PMID: 27003991 DOI: 10.3748/wjg.v22.i11.3150]
- 144 **Shafiee A**, Amini M, Emamirad H, Talebi Bezmin Abadi A. Recombination and phenotype evolution dynamic of Helicobacter pylori in colonized hosts. *Int J Syst Evol Microbiol* 2016; Epub ahead of print [PMID: 27082852 DOI: 10.1099/ijsem.0.001072]

**P- Reviewer:** Bernal G, Manguso F, Koch TR **S- Editor:** Ma YJ  
**L- Editor:** Webster JR **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

